Slingshot members are tracking this event:

Phase 3 REMARC Trial Data with REVLIMID in DLBCL Maintenance Due Q4 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Data from the Phase 3 Remarc Trial of Revlimid (lenalidomide) on patients with diffuse large b-cell lymphoma is expected in 2016.  The study primary completion date is projected in September.
Clinical Data Update on July 25 2016: REMARC achieved the primary endpoint of a statistically significant improvement in progression-free survival for patients receiving REVLIMID®. The interim analysis of overall survival, a key secondary endpoint, showed no benefit in the REVLIMID® arm. Based upon these interim results, Celgene does not currently plan to seek approval for this indication.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 25, 2016
Occurred Source:
Related Keywords Phase 3 Data, Remarc Trial, Revlimid, Lenalidomide, Diffuse Large B-cell Lymphoma